

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 215/52, A61K 31/47, C07D 409/04, 405/04, 401/04, 409/12, 221/18, 417/04, 401/12, 405/12	A1	(11) International Publication Number: WO 95/32948 (43) International Publication Date: 7 December 1995 (07.12.95)
(21) International Application Number: PCT/EP95/02000 (22) International Filing Date: 23 May 1995 (23.05.95) (30) Priority Data: MI94A001099 27 May 1994 (27.05.94) IT MI95A000494 14 March 1995 (14.03.95) IT (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM FARMACEUTICI S.P.A. [IT/IT]; Via Zambeletti, I-20021 Baranzate (IT). (72) Inventors; and (75) Inventors/Applicants (for US only): FARINA, Carlo [IT/IT]; SmithKline Beecham Farmaceutici S.p.A., Via Zambeletti, I-20021 Baranzate (IT). GIARDINA, Giuseppe, Arnaldo, Maria [IT/IT]; SmithKline Beecham Farmaceutici S.p.A., Via Zambeletti, I-20021 Baranzate (IT). GRUGNI, Mario [IT/IT]; SmithKline Beecham Farmaceutici S.p.A., Via Zambeletti, I-20021 Baranzate (IT). RAVEGLIA, Luca, Francesco [IT/IT]; SmithKline Beecham Farmaceutici S.p.A., Via Zambeletti, I-20021 Baranzate (IT).		(74) Agent: RUSSELL, Brian, John; SmithKline Beecham, Corporate Intellectual Property, SB House, Great West Road, Brentford, Middlesex TW8 9BD (GB). (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published With international search report. 96120415 -RTMP copy-
(54) Title: QUINOLINE DERIVATIVES AS TACHYKININ NK₃ RECEPTOR ANTAGONISTS (57) Abstract NK₃ receptor antagonists of formula (I) are useful in treating <i>inter alia</i> pulmonary disorders, CNS disorders and neurodegenerative disorders. (I)		